In another meta-analysis of 5 randomised clinical trials (n = 2317) BRAF/MEK inhibitors therapy was associated with an increased risk of LVEF decrease (RR, 3.72; 95% CI, 1.74–7.94; p < 0.001) and arterial hypertension (RR, 1.49; 95% CI, 1.12–1.97; p = 0.005) compared to BRAF inhibitor monotherapy [116]. Here, MAP2K7 is linked to Hypertension.